HK1176870A1 - 疾病的治療方法 - Google Patents
疾病的治療方法Info
- Publication number
- HK1176870A1 HK1176870A1 HK13103875.9A HK13103875A HK1176870A1 HK 1176870 A1 HK1176870 A1 HK 1176870A1 HK 13103875 A HK13103875 A HK 13103875A HK 1176870 A1 HK1176870 A1 HK 1176870A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diseases
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21918509P | 2009-06-22 | 2009-06-22 | |
US31535010P | 2010-03-18 | 2010-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1176870A1 true HK1176870A1 (zh) | 2013-08-09 |
Family
ID=43354875
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11107136.7A HK1153127A1 (en) | 2009-06-22 | 2011-07-11 | Method for treatment of diseases |
HK13103306.8A HK1176003A1 (zh) | 2009-06-22 | 2013-03-18 | 疾病的治療方法 |
HK13103875.9A HK1176870A1 (zh) | 2009-06-22 | 2013-03-27 | 疾病的治療方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11107136.7A HK1153127A1 (en) | 2009-06-22 | 2011-07-11 | Method for treatment of diseases |
HK13103306.8A HK1176003A1 (zh) | 2009-06-22 | 2013-03-18 | 疾病的治療方法 |
Country Status (25)
Country | Link |
---|---|
US (4) | US9233113B2 (zh) |
EP (7) | EP2554170A1 (zh) |
JP (2) | JP5833549B2 (zh) |
KR (1) | KR101877041B1 (zh) |
CN (3) | CN107050036A (zh) |
AU (1) | AU2010264524B2 (zh) |
BR (1) | BRPI1010087A2 (zh) |
CA (2) | CA2781771A1 (zh) |
DE (1) | DE202010017530U1 (zh) |
DK (6) | DK2554172T3 (zh) |
EA (1) | EA027524B1 (zh) |
ES (6) | ES2554688T3 (zh) |
HK (3) | HK1153127A1 (zh) |
HR (1) | HRP20130123T1 (zh) |
HU (1) | HUE028212T2 (zh) |
IL (1) | IL216951A (zh) |
MX (2) | MX336436B (zh) |
MY (1) | MY160127A (zh) |
NZ (2) | NZ615941A (zh) |
PL (6) | PL2326332T3 (zh) |
PT (5) | PT2326332E (zh) |
SG (7) | SG2014008163A (zh) |
SI (1) | SI2326332T1 (zh) |
WO (1) | WO2010151530A1 (zh) |
ZA (1) | ZA201109278B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2572223C (en) | 2004-06-25 | 2014-08-12 | The Johns Hopkins University | Angiogenesis inhibitors |
WO2007009087A2 (en) * | 2005-07-12 | 2007-01-18 | Dmi Biosciences, Inc. | Methods and products for treatment of diseases |
AU2010264525B2 (en) * | 2009-06-22 | 2015-04-02 | Ampio Pharmaceuticals, Inc. | Methods and products for treatment of diseases |
CA2781771A1 (en) | 2009-06-22 | 2010-12-29 | Dmi Acquisition Corp. | Pharmaceutical dosage forms and compositions comprising danazol |
WO2013052869A1 (en) * | 2011-10-07 | 2013-04-11 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
AU2013327393B2 (en) * | 2012-10-02 | 2019-07-18 | Centenary Institute Of Cancer Medicine And Cell Biology | Modulation of RNA activity and vascular permeability |
US9351979B2 (en) * | 2012-12-19 | 2016-05-31 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
JP6057333B2 (ja) * | 2013-02-25 | 2017-01-11 | 国立大学法人浜松医科大学 | 血管透過性亢進抑制作用の評価方法 |
US9880778B2 (en) | 2015-11-09 | 2018-01-30 | Google Inc. | Memory devices and methods |
WO2019090171A1 (en) * | 2017-11-04 | 2019-05-09 | Massachusetts Institute Of Technology | Compositions and methods to increase muscular strength |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL241544A (zh) | 1958-07-23 | |||
US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
GB1123770A (en) | 1966-11-15 | 1968-08-14 | Sterling Drug Inc | 2-cyano-3-oxo-steroids |
US4160027A (en) * | 1977-12-20 | 1979-07-03 | Sterling Drug Inc. | Steroid cyanoketones and intermediates |
FR2502098A1 (fr) | 1981-03-23 | 1982-09-24 | Huret & Fils | Dispositif perfectionne de fixation d'un derailleur sur une patte de cadre |
US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5714481A (en) * | 1983-08-02 | 1998-02-03 | Research Corporation Technologies, Inc. | Derivatives of 5-androsten-17 ones and 5-androstan-17-ones |
US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4837212A (en) * | 1984-11-15 | 1989-06-06 | University Of Miami | Treatment of hemolytic anemia with danazol |
US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
AU604236B2 (en) | 1986-04-28 | 1990-12-13 | Iolab, Inc. | Intraocular dosage compositions and method of use |
DE3738620A1 (de) * | 1987-11-13 | 1989-05-24 | Luderschmidt Christoph | Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie |
US5407926A (en) | 1987-12-29 | 1995-04-18 | Alcon Laboratories, Inc. | Ophthalmic composition |
JP2680614B2 (ja) | 1988-08-01 | 1997-11-19 | 日清製粉株式会社 | ダナゾール組成物 |
US5990099A (en) * | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
US5372996A (en) * | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
DE69032648T2 (de) * | 1989-07-07 | 1999-04-08 | Endorecherche Inc | Androgenderivate zur Hemming der Aktivität der Sexualsteroide |
AU657690B2 (en) | 1990-06-11 | 1995-03-23 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
US5972922A (en) * | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
JPH04149132A (ja) | 1990-10-13 | 1992-05-22 | Bairon Boeki Kk | ダナゾール水溶液 |
JPH0735335B2 (ja) | 1991-02-28 | 1995-04-19 | 五十嵐 正雄 | 子宮内膜症の治療薬 |
US5506220A (en) * | 1991-06-18 | 1996-04-09 | Laboratoire Theramex Sa | Anti-glaucomatous pharmaceutical composition and the process for obtaining them |
US5679666A (en) * | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
CA2425849C (en) | 1991-11-22 | 2007-02-27 | Alcon Laboratories, Inc. | Angiostatic steroids |
GB9200210D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
DK0643581T3 (da) * | 1992-04-21 | 2000-04-25 | Schepens Eye Res Inst | Okulær androgenbehandling ved Sjögren's syndrom |
ES2068742B1 (es) | 1993-02-11 | 1995-11-16 | Uriach & Cia Sa J | Nuevos derivados de piridinio. |
US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
US6060462A (en) | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
US5646136A (en) | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
EP0754046A1 (en) | 1994-04-04 | 1997-01-22 | FREEMAN, William R. | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
US5885591A (en) | 1996-07-02 | 1999-03-23 | Johnson & Johnson Consumer Products, Inc. | Personal lubricant compositions |
US5929111A (en) * | 1996-12-18 | 1999-07-27 | Alcon Laboratories, Inc. | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure |
US5993856A (en) * | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
WO1998043647A1 (en) * | 1997-03-28 | 1998-10-08 | Massachusetts Institute Of Technology, Inc. | Regulation of amyloid precursor protein (app) expression by estrogenic compounds |
US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
EP0939124A3 (en) | 1998-02-24 | 2001-03-21 | Smithkline Beecham Plc | MGBP1 sequences |
GB9807809D0 (en) | 1998-04-09 | 1998-06-10 | Multimed Ltd | Compositions comprising ethisterone or its derivatives |
US6645954B2 (en) * | 1998-04-09 | 2003-11-11 | Multimed Limited | Compositions comprising ethisterone or its derivatives |
CA2336703A1 (en) | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
US20040063719A1 (en) * | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
EP1022027A1 (en) * | 1999-01-22 | 2000-07-26 | Applied Research Systems ARS Holding N.V. | Tumor necrosis factor antagonists and their use in endometriosis |
DE69903278D1 (de) | 1999-07-09 | 2002-11-07 | Inst Pasteur De Lille Lille | Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit |
US6610674B1 (en) * | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
BR0014929B1 (pt) * | 1999-10-21 | 2009-01-13 | dispositivo para distribuiÇço de medicamento oftÁlmico. | |
WO2001030337A2 (en) | 1999-10-22 | 2001-05-03 | Orbon Corporation | Ophthalmic formulation of dopamine antagonists |
US6562369B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
AU2001230864A1 (en) | 2000-01-12 | 2001-07-24 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
GB2345851B (en) | 2000-01-18 | 2004-05-26 | Gavin Paul Vinson | A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour |
US20020055512A1 (en) * | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
AU785285B2 (en) | 2000-03-10 | 2006-12-21 | Sun Pharma Global Fze | Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
ES2381775T3 (es) | 2000-08-04 | 2012-05-31 | Dmi Biosciences, Inc. | Procedimiento del uso de dicetopiperazinas y composición que las contiene |
US20040082557A1 (en) * | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
JP2004537506A (ja) | 2001-03-01 | 2004-12-16 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 血液細胞欠乏症を治療するためのある種のステロイドの使用 |
GB2375958B (en) * | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
US20030003144A1 (en) * | 2001-05-01 | 2003-01-02 | Keller Brian C. | Sustained release formulations for nifedipine, dextromethorphan, and danazol |
AU2002344237B8 (en) | 2001-05-29 | 2008-11-06 | Sirna Therapeutics, Inc. | Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions |
FR2825277B1 (fr) | 2001-05-30 | 2004-10-15 | Oreal | Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd |
US20030050291A1 (en) * | 2001-06-12 | 2003-03-13 | Yadon Arad | Adrenal enzyme inhibitors |
US20030232798A1 (en) * | 2001-06-12 | 2003-12-18 | Yadon Arad | Adrenal enzyme inhibitors |
EP1413315A4 (en) * | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | DRUGS WITH CONTINUOUS RELEASE |
JP2006506321A (ja) * | 2002-04-11 | 2006-02-23 | チルドレンズ メディカル センター コーポレーション | 血管透過性亢進を阻害する方法 |
AU2003278744B2 (en) * | 2002-08-28 | 2010-07-29 | Harbor Biosciences, Inc. | Therapeutic treatment methods |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
ES2263072T3 (es) | 2002-12-18 | 2006-12-01 | Laboratoires Besins International | Tratamiento de la mastalgia con 4-hidroxi tamoxifeno. |
AU2003297511B2 (en) | 2002-12-20 | 2010-01-21 | Chakshu Research, Inc. | Ophthalmic formulation for the prevention and treatment of ocular conditions |
CA2764405A1 (en) | 2003-01-02 | 2004-07-22 | Femmepharma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
CN100342856C (zh) * | 2003-04-10 | 2007-10-17 | 上海医药工业研究院 | 达那唑半固体骨架制剂的组合物 |
GB2400554B (en) | 2003-04-16 | 2007-04-18 | George Margetts | Treatment of angiotensin II-induced cardiovascular disease |
WO2004103406A1 (ja) | 2003-05-26 | 2004-12-02 | Japan Science And Technology Agency | 血小板の減少または増加を伴う疾患の治療用組成物 |
GB0313612D0 (en) * | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
WO2005053660A2 (en) * | 2003-12-03 | 2005-06-16 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising danazol |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20050143362A1 (en) * | 2003-12-31 | 2005-06-30 | Mclane Michael W. | Danazol for treatment of hypogonadism in the adult male |
US7442681B2 (en) * | 2004-02-10 | 2008-10-28 | University Of Virginia Patent Foundation | Method of inhibiting vascular permeability |
WO2005091853A2 (en) | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
NZ550088A (en) | 2004-04-06 | 2009-08-28 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
CA2572223C (en) | 2004-06-25 | 2014-08-12 | The Johns Hopkins University | Angiogenesis inhibitors |
GB2420281A (en) | 2004-11-22 | 2006-05-24 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of dermatological conditions |
GB2421183A (en) | 2004-12-17 | 2006-06-21 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of skin cancers |
EP1848541A4 (en) | 2005-02-07 | 2013-01-16 | Pharmalight Inc | METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS |
US8841259B2 (en) | 2005-02-24 | 2014-09-23 | Joslin Diabetes Center | Compositions and methods for treating vascular permeability |
WO2006094027A2 (en) | 2005-03-02 | 2006-09-08 | Nascent Pharmaceutical, Inc. | Combination therapy for topical application |
WO2007009087A2 (en) * | 2005-07-12 | 2007-01-18 | Dmi Biosciences, Inc. | Methods and products for treatment of diseases |
US8404643B2 (en) * | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
WO2007109363A2 (en) | 2006-03-20 | 2007-09-27 | The Johns Hopkins University | Methods and compositions for inhibiting impdh isoform 1 |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US8071779B2 (en) * | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
CN101024082A (zh) | 2007-04-06 | 2007-08-29 | 张士东 | 一种全面预防和治疗心脑血管疾病复方药及其应用 |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
WO2009036108A1 (en) * | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
JP5767812B2 (ja) | 2007-12-06 | 2015-08-19 | バーグ リミテッド ライアビリティ カンパニー | 生物学的利用率が向上した吸入可能な組成物 |
JP5856843B2 (ja) * | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ,インコーポレイテッド | ジケトピペラジンを用いた医薬組成物 |
AU2010264525B2 (en) * | 2009-06-22 | 2015-04-02 | Ampio Pharmaceuticals, Inc. | Methods and products for treatment of diseases |
CA2781771A1 (en) * | 2009-06-22 | 2010-12-29 | Dmi Acquisition Corp. | Pharmaceutical dosage forms and compositions comprising danazol |
WO2013052869A1 (en) | 2011-10-07 | 2013-04-11 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
US9351979B2 (en) | 2012-12-19 | 2016-05-31 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
-
2010
- 2010-06-22 CA CA2781771A patent/CA2781771A1/en not_active Abandoned
- 2010-06-22 MX MX2014006692A patent/MX336436B/es unknown
- 2010-06-22 ES ES12007365.5T patent/ES2554688T3/es active Active
- 2010-06-22 DK DK12007362.2T patent/DK2554172T3/da active
- 2010-06-22 ES ES12007361.4T patent/ES2523821T3/es active Active
- 2010-06-22 PT PT107925679T patent/PT2326332E/pt unknown
- 2010-06-22 CA CA2751002A patent/CA2751002C/en not_active Expired - Fee Related
- 2010-06-22 SI SI201030136T patent/SI2326332T1/sl unknown
- 2010-06-22 EP EP12007360A patent/EP2554170A1/en not_active Withdrawn
- 2010-06-22 CN CN201610971162.9A patent/CN107050036A/zh active Pending
- 2010-06-22 NZ NZ615941A patent/NZ615941A/en not_active IP Right Cessation
- 2010-06-22 PL PL10792567T patent/PL2326332T3/pl unknown
- 2010-06-22 PT PT110092392T patent/PT2425839E/pt unknown
- 2010-06-22 WO PCT/US2010/039458 patent/WO2010151530A1/en active Application Filing
- 2010-06-22 PL PL12007362T patent/PL2554172T3/pl unknown
- 2010-06-22 PT PT120073614T patent/PT2554171E/pt unknown
- 2010-06-22 DK DK12007365.5T patent/DK2554174T3/da active
- 2010-06-22 SG SG2014008163A patent/SG2014008163A/en unknown
- 2010-06-22 BR BRPI1010087A patent/BRPI1010087A2/pt not_active IP Right Cessation
- 2010-06-22 PT PT120073622T patent/PT2554172E/pt unknown
- 2010-06-22 EP EP12007363.0A patent/EP2554173B1/en active Active
- 2010-06-22 EP EP12007362.2A patent/EP2554172B1/en not_active Not-in-force
- 2010-06-22 SG SG2014009799A patent/SG2014009799A/en unknown
- 2010-06-22 CN CN201610480273.XA patent/CN106109475A/zh active Pending
- 2010-06-22 PL PL11009239T patent/PL2425839T3/pl unknown
- 2010-06-22 SG SG2014008171A patent/SG2014008171A/en unknown
- 2010-06-22 JP JP2012517645A patent/JP5833549B2/ja not_active Expired - Fee Related
- 2010-06-22 PL PL12007365T patent/PL2554174T3/pl unknown
- 2010-06-22 DE DE202010017530U patent/DE202010017530U1/de not_active Expired - Lifetime
- 2010-06-22 EP EP10792567A patent/EP2326332B1/en active Active
- 2010-06-22 EA EA201200036A patent/EA027524B1/ru not_active IP Right Cessation
- 2010-06-22 SG SG2011094620A patent/SG176939A1/en unknown
- 2010-06-22 EP EP11009239.2A patent/EP2425839B1/en not_active Not-in-force
- 2010-06-22 PT PT120073655T patent/PT2554174E/pt unknown
- 2010-06-22 PL PL12007361T patent/PL2554171T3/pl unknown
- 2010-06-22 NZ NZ597030A patent/NZ597030A/xx not_active IP Right Cessation
- 2010-06-22 AU AU2010264524A patent/AU2010264524B2/en not_active Ceased
- 2010-06-22 MY MYPI2011006154A patent/MY160127A/en unknown
- 2010-06-22 ES ES10792567T patent/ES2398322T3/es active Active
- 2010-06-22 HU HUE12007365A patent/HUE028212T2/en unknown
- 2010-06-22 ES ES11009239.2T patent/ES2523769T3/es active Active
- 2010-06-22 MX MX2011013777A patent/MX2011013777A/es active IP Right Grant
- 2010-06-22 EP EP12007365.5A patent/EP2554174B1/en not_active Not-in-force
- 2010-06-22 DK DK10792567.9T patent/DK2326332T3/da active
- 2010-06-22 ES ES12007362.2T patent/ES2523068T3/es active Active
- 2010-06-22 SG SG2014009807A patent/SG2014009807A/en unknown
- 2010-06-22 PL PL12007363T patent/PL2554173T3/pl unknown
- 2010-06-22 ES ES12007363.0T patent/ES2612748T3/es active Active
- 2010-06-22 DK DK11009239.2T patent/DK2425839T3/en active
- 2010-06-22 DK DK12007361.4T patent/DK2554171T3/da active
- 2010-06-22 CN CN2010800372358A patent/CN102481304A/zh active Pending
- 2010-06-22 EP EP12007361.4A patent/EP2554171B1/en not_active Not-in-force
- 2010-06-22 SG SG2014009781A patent/SG2014009781A/en unknown
- 2010-06-22 US US12/820,398 patent/US9233113B2/en not_active Expired - Fee Related
- 2010-06-22 KR KR1020127001781A patent/KR101877041B1/ko active IP Right Grant
- 2010-06-22 DK DK12007363.0T patent/DK2554173T3/en active
- 2010-06-22 SG SG2014008155A patent/SG2014008155A/en unknown
-
2011
- 2011-07-11 HK HK11107136.7A patent/HK1153127A1/xx not_active IP Right Cessation
- 2011-10-19 US US13/276,810 patent/US8227457B2/en not_active Expired - Fee Related
- 2011-12-01 US US13/308,754 patent/US20120077789A1/en not_active Abandoned
- 2011-12-13 IL IL216951A patent/IL216951A/en not_active IP Right Cessation
- 2011-12-15 ZA ZA2011/09278A patent/ZA201109278B/en unknown
-
2013
- 2013-02-12 HR HRP20130123AT patent/HRP20130123T1/hr unknown
- 2013-03-18 HK HK13103306.8A patent/HK1176003A1/zh not_active IP Right Cessation
- 2013-03-27 HK HK13103875.9A patent/HK1176870A1/zh not_active IP Right Cessation
-
2015
- 2015-08-06 JP JP2015155819A patent/JP2015214575A/ja not_active Withdrawn
- 2015-12-02 US US14/956,760 patent/US9987292B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217763A1 (zh) | 用於治療疾病的方法 | |
HK1169804A1 (zh) | 治療疼痛的方法 | |
HK1176870A1 (zh) | 疾病的治療方法 | |
PT2429524T (pt) | Formulação de ac220 seca por atomização | |
EP2350641A4 (en) | Methods of Treatment | |
EP2544686A4 (en) | COMBINED METHODS FOR THE TREATMENT OF DISEASES | |
EP2416803A4 (en) | NEW METHODS OF TREATING INFLAMMATORY DISEASES | |
PL2281457T3 (pl) | Sposób fizycznego działania na rośliny | |
EP2424539A4 (en) | PROCESS FOR TREATING DEPRESSION | |
EP2585103A4 (en) | METHOD OF TREATMENT | |
EP2440238A4 (en) | Methods of Treatment | |
GB0921823D0 (en) | Method of treatment | |
GB0909807D0 (en) | Method of treatment | |
GB0904164D0 (en) | Method of treatment | |
AU2009903360A0 (en) | Method of Treatment | |
EP2532254A4 (en) | METHOD FOR PROCESSING A LACTO-N BIOSE-CONTAINED SOLUTION | |
GB0823435D0 (en) | Method of treatment | |
GB201000318D0 (en) | Method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210621 |